Conclusion: The Right Cells for the Right Patients
At Longevity Medical Institute, our responsibility is to provide patients with therapies that are not only cutting-edge but also safe, effective, and backed by evidence. That’s why we’ve built our regenerative platform around five MSC sources — placental, Wharton’s jelly, adipose, endometrial, and dental pulp — and enhanced it with exosomes to maximize their effect.
We choose MSCs because:
They are natural and abundant, isolated directly from human tissues without genetic reprogramming.
They are safe, with decades of global research and tens of thousands of patients treated worldwide.
They are clinically relevant, with the strongest body of evidence for arthritis, orthopedic injuries, tendon and ligament repair, autoimmune balance, systemic inflammation, and longevity medicine.
They are proven at scale, with regulatory-approved MSC products already in use internationally, confirming both manufacturability and clinical utility.
They are supported by overwhelming data: 50+ years of study, 80,000+ papers, 1,500+ trials, and widespread real-world application.
By comparison, MUSE cells are scientifically intriguing but still early-stage. While they are naturally occurring, stress-tolerant, and non-tumorigenic in studies, clinical research is limited (<600 papers, <10 trials, and only a few hundred patients worldwide). To date, their use has focused on conditions like stroke and heart attack, with no substantial evidence in orthopedics, musculoskeletal repair, or anti-aging.
Longevity Medical Institute (C) Copyright. All Rights Reserved.
08
Made with FlippingBook Digital Proposal Creator